AbSci Overview

  • Founded
  • 2011

Founded
  • Status
  • Public

  • Employees
  • 213

Employees
  • Stock Symbol
  • ABSI

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $1.73

  • (As of Monday Closing)

AbSci General Information

Description

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Contact Information

Website
www.absci.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 18105 SouthEast Mill Plain Boulevard
  • Vancouver, WA 98683
  • United States
+1 (360) 000-0000

AbSci Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbSci Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.73 $1.72 $1.53 - $9.09 $159M 92.4M 484K -$1.22

AbSci Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 108,067 501,703
Revenue 5,642 4,782 4,780 2,060
EBITDA (98,567) (99,773) (12,588) (5,825)
Net Income (110,599) (100,960) (14,353) (6,584)
Total Assets 339,387 426,195 88,569 19,471
Total Debt 22,138 20,011 14,500 6,016
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AbSci Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AbSci‘s full profile, request access.

Request a free trial

AbSci Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the n
Drug Discovery
Vancouver, WA
213 As of 2022
00000
0.000 0000-00-00
00000000 00000

000000

lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla paria
0000 000000000
Dusseldorf, Germany
00 As of 0000
0000000000

000000

piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000 000000000
San Carlos, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbSci Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NUMAFERM Venture Capital-Backed Dusseldorf, Germany 00 0000000000
00000000 Formerly VC-backed San Carlos, CA 00 00000 000000000 00000
00000 0000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000 00000000000 Corporate Backed or Acquired Richmond, CA 000000000 -
000000000 Formerly VC-backed Piscataway, NJ 0000 00000 000000000 00000
You’re viewing 5 of 29 competitors. Get the full list »

AbSci Patents

AbSci Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021259323-A1 Polypeptide cleavage methods Pending 20-Apr-2020 000000000
CA-3180693-A1 Polypeptide cleavage methods Pending 20-Apr-2020 000000000
EP-4139329-A2 Polypeptide cleavage methods Pending 20-Apr-2020 000000000
AU-2021218706-A1 Proximity assay Pending 11-Feb-2020 0000000000
CA-3170531-A1 Proximity assay Pending 11-Feb-2020 G01N33/542
To view AbSci’s complete patent history, request access »

AbSci Executive Team (16)

Name Title Board Seat Contact Info
Sean McClain Chief Executive Officer & Board Member
Gregory Schiffman Chief Financial Officer, Finance
Nikhil Goel Chief Strategy Officer
Matthew Weinstock Chief Technology Officer, Technology
Jack Gold Chief Marketing Officer
You’re viewing 5 of 16 executive team members. Get the full list »

AbSci Board Members (13)

Name Representing Role Since
Amrit Nagpal Redmile Group Board Member 000 0000
Daniel Gold Ph.D AbSci Board Member 000 0000
Daniel Rabinovitsj AbSci Board Member 000 0000
Gustavo Mahler Ph.D Self Board Member 000 0000
Ivana Magovcevic-Liebisch Ph.D Self Chairman & Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

AbSci Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbSci Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AbSci‘s full profile, request access.

Request a free trial

AbSci Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 04-Jun-2021 0000000000 00000 Drug Discovery 0000 0000
Denovium 12-Jan-2021 Merger/Acquisition Decision/Risk Analysis 0000 0000
To view AbSci’s complete acquisitions history, request access »

AbSci Subsidiaries (1)

Company Name Industry Location Founded
0000000 Drug Discovery Cambridge, MA 0000
To view AbSci’s complete subsidiaries history, request access »

AbSci ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

25.55 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,231

Rank

00.00

Percentile

Commercial Services

Industry

00 of 430

Rank

00.00

Percentile

Business Support Services

Subindustry

00 of 159

Rank

00.00

Percentile

To view AbSci’s complete esg history, request access »